{"id":"W4309184100","doi":"10.1001/jamaoncol.2022.5228","title":"Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors","year":2022,"lang":"en","type":"letter","venue":"JAMA Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Foundation Medicine; Genentech; Astellas Pharma; Incyte; National Center for Advancing Translational Sciences; Seagen; Gilead Sciences; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Symphogen; GlaxoSmithKline; Amgen; Pfizer","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Avelumab; Cancer; Lung cancer; Breast cancer; Immunogenicity; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Immunotherapy; Antigen; Immunology; Phases of clinical research; Chemotherapy; Clinical trial; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006080308,0.0003448316,0.001098259,0.000238541,0.0001479559,0.0003871543,0.0002461951,0.0003241477,0.001796565],"category_scores_gemma":[0.0007218908,0.0001611616,0.0006949486,0.000339656,0.0001938958,0.0003654126,0.0001714005,0.0007410152,0.0003358969],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004010998,"about_ca_system_score_gemma":0.0006846726,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000385134,"about_ca_topic_score_gemma":0.001410323,"domain_scores_codex":[0.9997773,0.0001019288,0.00002106599,0.00003685558,0.00002592741,0.00003688087],"domain_scores_gemma":[0.9996835,0.00007580757,0.0001055249,0.00001504255,0.00001823206,0.0001019105],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.5539026,0.008260836,0.03562929,0.001956542,0.002208114,0.0003728254,0.0001299371,0.003352271,0.03837106,0.0003949514,0.006013246,0.3494084],"study_design_scores_gemma":[0.4033087,0.4561914,0.1018971,0.000291029,0.002235507,0.001449456,0.0001081071,0.004894293,0.009408398,0.0006223926,0.01954936,0.00004424375],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"other","genre_scores_codex":[0.9816332,0.01373869,0.0004281309,0.0004877472,0.0001260487,0.0004880566,0.0006225888,0.00006467158,0.0024108],"genre_scores_gemma":[0.9941838,0.002869783,0.0006617388,0.0003516218,0.0001519841,0.0003240721,0.0006675891,0.000006166092,0.00078326],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.001796565,"threshold_uncertainty_score":0.006010115,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01410302039239859,"score_gpt":0.3020944315400396,"score_spread":0.287991411147641,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}